Glioma

CASE REPORT
Year
: 2022  |  Volume : 5  |  Issue : 3  |  Page : 107--109

WHO grade III diffuse astrocytic glioma in a 35-year-old male


Rong Du, Huandong Liu, Guoqing Yi, Huilin Cheng, Ping Liang 
 Department of Neurosurgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province, China

Correspondence Address:
Dr. Ping Liang
Department of Neurosurgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009
China

Gliomas are tumors that originate from glial cells and the most common neoplasms in the central nervous system. The World Health Organization (WHO) has classified glioma into four grades, I to IV, with multidisciplinary therapies required for the management of high-grade gliomas (grades III and IV). Molecular pathology has become increasingly critical in guiding the treatment and predicting the prognosis of patients with gliomas. A 35-year-old man diagnosed with WHO grade III diffuse astrocytic glioma initially underwent surgical resection, followed by immunohistochemical and molecular diagnosis. The patient was administered adjuvant radiotherapy and chemotherapy based on the molecular characteristics of the tumor. Long term follow-up showed a relatively satisfactory therapeutic response. Molecular classification may help guide decisions on the comprehensive treatment of patients with WHO grade III diffuse astrocytic glioma. This study was approved by the Ethics Committee of Zhongda Hospital of Southeast University, China (approval No. 20211015001, approval date: October 15, 2021).


How to cite this article:
Du R, Liu H, Yi G, Cheng H, Liang P. WHO grade III diffuse astrocytic glioma in a 35-year-old male.Glioma 2022;5:107-109


How to cite this URL:
Du R, Liu H, Yi G, Cheng H, Liang P. WHO grade III diffuse astrocytic glioma in a 35-year-old male. Glioma [serial online] 2022 [cited 2022 Dec 1 ];5:107-109
Available from: http://www.jglioma.com/article.asp?issn=2589-6113;year=2022;volume=5;issue=3;spage=107;epage=109;aulast=Du;type=0